Slate Run Pharmaceuticals recalls
2 notices naming Slate Run Pharmaceuticals as the recalling firm, since March 26, 2025. A notice covers specific products and lots, not every product of the firm.
Hazard and remedy text is quoted from the agency, unedited. The tag names the kind of risk with a word from that text. Every notice links to its official page.
Slate Run Pharmaceuticals: Eptifibatide Injection
Hazard (FDA): Labeling: Not Elsewhere Classified. The carton for Eptifibatide Injection 75 mg/100 mL states 75 mg/100 mL vial for weight-adjusted bolus dosing. The approved statement is 75 mg/100 mL vial for weight-adjusted infusion.
FDAMedicines
Slate Run Pharmaceuticals: Cinacalcet Hydrochloride Tablets 30 mg and 1 more
Hazard (FDA): CGMP deviations: The presence of nitrosamine impurity above the acceptable daily intake limits.
FDAMedicines